Detalles de la búsqueda
1.
Considerations for pooling real-world data as a comparator cohort to a single arm trial: a simulation study on assessment of heterogeneity.
BMC Med Res Methodol
; 23(1): 193, 2023 08 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-37620758
2.
Response- and Progression-Based End Points in Trial and Observational Cohorts of Patients With NSCLC.
JAMA Netw Open
; 7(5): e249286, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38700864
3.
A systematic approach towards missing lab data in electronic health records: A case study in non-small cell lung cancer and multiple myeloma.
CPT Pharmacometrics Syst Pharmacol
; 12(9): 1201-1212, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37322818
4.
Emulating Randomized Controlled Trials with Hybrid Control Arms in Oncology: A Case Study.
Clin Pharmacol Ther
; 113(4): 867-877, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36606735
5.
Concordance of Clinician-Documented and Imaging Response in Patients With Stage IV Non-Small Cell Lung Cancer Treated With First-Line Therapy.
JAMA Netw Open
; 5(5): e229655, 2022 05 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35552726
6.
Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerations.
Contemp Clin Trials Commun
; 30: 101000, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36186544
7.
Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC.
Adv Ther
; 38(4): 1843-1859, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33674928
8.
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.
Oncologist
; 15(12): 1329-34, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-21147867
9.
Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
Cancer Chemother Pharmacol
; 80(6): 1079-1090, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29022084
10.
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.
Clin Cancer Res
; 22(15): 3755-63, 2016 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26920887
11.
Small But Mighty: The Use of Real-World Evidence to Inform Precision Medicine.
Clin Pharmacol Ther
; 106(1): 87-90, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31112289
12.
Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.
J Clin Oncol
; 32(25): 2750-7, 2014 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25024070
13.
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.
Cancer Chemother Pharmacol
; 74(2): 399-410, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24939213
14.
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.
Neuro Oncol
; 13(1): 143-51, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21084434
15.
Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.
J Thorac Oncol
; 5(3): 354-60, 2010 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-20032789
16.
Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.
J Clin Oncol
; 27(9): 1405-12, 2009 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-19224857
Resultados
1 -
16
de 16
1
Próxima >
>>